Natixis’s Nektar Therapeutics NKTR Stock Holding History

Natixis’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$47.8K	Hold	685	–	–	﹤0.01%	1031
2026 Q1	$49.3K	Hold	685	–	–	﹤0.01%	983
2025 Q4	$29K	Buy	+685	New	+$38.3K	﹤0.01%	1024
2022 Q2	–	Sell	-3,146	Closed	-$254K	–	1286
2022 Q1	$254K	Buy	+3,146	New	+$466K	﹤0.01%	1082
2019 Q3	–	Sell	-2,792	Closed	-$1.49M	–	887
2019 Q2	$1.49M	Buy	2,792 +145	+5%	+$72.7K	0.01%	484
2019 Q1	$1.3M	Sell	2,647 -749	-22%	-$444K	0.01%	547
2018 Q4	$1.67M	Buy	3,396 +1,514	+80%	+$914K	0.01%	446
2018 Q3	$1.72M	Buy	+1,882	New	+$1.61M	0.01%	504
2018 Q1	–	Sell	-1,072	Closed	-$960K	–	946
2017 Q4	$960K	Buy	1,072 +287	+37%	+$170K	0.01%	505
2017 Q3	$283K	Buy	+785	New	+$246K	﹤0.01%	935
2017 Q2	–	Sell	-1,102	Closed	-$388K	–	940
2017 Q1	$388K	Buy	+1,102	New	+$248K	﹤0.01%	590

Other funds holding NKTR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Natixis's NKTR Position: Q2 2026 in Review

Natixis held its Nektar Therapeutics (NKTR) position steady in Q2 2026 at 685 shares worth $47.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1031.

Natixis first reported a position in NKTR in Q1 2017 and has held it in 11 quarters since. The position peaked at $1.72M in Q3 2018. 239 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

Natixis held 685 shares of Nektar Therapeutics worth $47.8K as of Q2 2026.
Natixis left its Nektar Therapeutics share count unchanged in Q2 2026.
Nektar Therapeutics made up ﹤0.01% of Natixis's portfolio in Q2 2026, its #1031 holding.
Natixis first reported a position in Nektar Therapeutics in Q1 2017 and has held it in 11 quarters since.
Natixis's Nektar Therapeutics position peaked at $1.72M in Q3 2018.
239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Natixis's 13F filing for Q2 2026, filed 13 Aug 2026.